WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced the appointment of Henry Levy as executive vice president of client development and commercial services. Levy leads PPD’s customer-facing teams to optimize strategies and deliver results through cross-functional collaboration across the full range of clinical research services.
“With two decades of industry experience, Henry brings an impressive track record of relationship-building at the highest levels of the industry to enhance PPD’s efforts to fuel innovation and R&D success for our biopharmaceutical clients,” said David Simmons, PPD’s chairman and chief executive officer. “He is a welcome addition to PPD’s senior leadership team and shares our passion for serving clients with the industry’s most responsive, strategic and forward-thinking teams and solutions.”
Levy joined PPD from Accenture, where for the past 21 years he built a strong reputation helping biopharmaceutical clients define and deliver on high-performance strategies. Most recently, he served as global managing director of Accenture’s life sciences research and development practice. Levy’s experience also includes working with biopharmaceutical industry leaders to drive pre-competitive collaboration solutions.
Levy earned a bachelor’s degree in bioengineering from the University of Pennsylvania.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s new executive vice president, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; the ability to control SG&A spending; risks associated with acquisitions and investments rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; consolidation in the pharmaceutical and biotechnology industries; risks associated with and dependence on strategic relationships; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.